Blue Water Vaccines (BWV US): Synthetic Expert Call Transcript (15 Aug 2026)
Onconetix is facing severe liquidity constraints with only $5.4 million in cash as of August 10, 2026, and an accumulated deficit of $138.3...
95 Views
IPO Databook: Onconetix (ONCO US) - Aug 2026
Onconetix, Inc. is a commercial stage biotechnology company focused on oncology solutions, primarily its Proclarix in vitro diagnostic test. This...
91 Views
No more insights